Aurobindo Pharma

BSE: 524804 | NSE: AUROPHARMA | ISIN: INE406A01037 | SECTOR: Major Drugs

1,152.45

0.65 (0.06%)
30 Apr 2024, 03:52 PM IST

Key Metrics

Influencer Count

-

Simple Moving Averages

DaysBSENSE

51,102.701,102.73
101,103.691,103.91
201,099.391,099.55
501,059.071,059.20
1001,067.841,067.93
300967.00967.13

News

Company Description

Aurobindo Pharma Limited is an India-based pharmaceutical company. The Company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, generic pharmaceuticals and related services. Its product portfolio is spread over seven therapeutic/product areas encompassing Central nervous systems (CNS), Antiretrovirals (ARVs), Cardiovascular (CVS), SSP - Orals & Sterile, Anti-infectives, Anti-diabetics and Cephalosporins - Orals. It is engaged in developing a range of oncology and hormonal products. It is developing topical as well as transdermal products in the dermatology therapeutic segment. It is also developing about three depot injections based on the microsphere and nano-suspension technology platforms. The Company is marketing its products globally in approximately 150 countries. The Company's subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited, and others.

Company Officers